Windtree Therapeutics, Inc.
WINT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | -0.02 |
| FCF Yield | -1,677.94% | -482.85% | -363.49% | -60.25% |
| EV / EBITDA | -0.65 | -0.76 | -0.04 | -0.46 |
| Quality | ||||
| ROIC | -328.22% | -60.32% | -110.48% | -95.26% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 8.62 | 0.66 | 0.50 | 0.35 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | -14.59% | 30.89% | 18.70% | 6.49% |
| Safety | ||||
| Net Debt / EBITDA | -0.03 | -0.62 | 0.10 | 0.06 |
| Interest Coverage | -106.46 | -350.78 | -779.87 | -677.89 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -8,164.70 | -3,601.04 | -85.66 | -291.08 |